Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
- Conditions
- Breast CancerCancer of BreastCancer of the BreastTumors, BreastBreast TumorMalignant Tumor of Breast
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT06471673
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Conditions
- Metastatic Breast CancerBreast NeoplasmEnd Stage CancerBreast CancerBreast Cancer Metastatic
- Interventions
- Drug: Treatment of Physician's ChoiceDrug: Interferon infiltration of the inoculation site
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 404
- Registration Number
- NCT06072612
- Locations
- 🇺🇸
University of Arizona-Cancer Center, Tucson, Arizona, United States
🇺🇸Los Angeles cancer Network_Anaheim, Anaheim, California, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
Combination Study of SV-BR-1-GM With Retifanlimab
- Conditions
- Breast CancerBreast Cancer MetastaticBreast NeoplasmMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT03328026
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
- Conditions
- BreastcancerBreast Neoplasm
- Interventions
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT03066947
- Locations
- 🇺🇸
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸University of Miami/Sylvester at Plantation, Plantation, Florida, United States
🇺🇸Cancer Center of Kansas (CCK), Wichita, Kansas, United States
News
Blood Test Monitoring PD-L1 Expression Shows Promise for Improving Immunotherapy Outcomes in Metastatic Breast Cancer
Clinical trials demonstrate that the LifeTracDx® blood test can monitor PD-L1 upregulation in metastatic breast cancer patients, with 76% showing increased expression after leronlimab treatment.